Current and historical daily PE Ratio for Spero Therapeutics Inc (
STU:2HA
) from 2019 to Apr 18 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Spero Therapeutics stock (STU:2HA) PE ratio as of Apr 18 2024 is 3.43.
More Details
Spero Therapeutics Inc (STU:2HA) PE Ratio (TTM) Chart
Spero Therapeutics Inc (STU:2HA) PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Total 1206
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Spero Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-18 | 3.6 | 2024-02-13 | 3.5 |
| 2024-04-17 | 3.6 | 2024-02-12 | 3.5 |
| 2024-04-16 | 3.6 | 2024-02-09 | 3.2 |
| 2024-04-15 | 3.8 | 2024-02-08 | 3.2 |
| 2024-04-12 | 4.0 | 2024-02-07 | 3.4 |
| 2024-04-11 | 4.1 | 2024-02-06 | 3.4 |
| 2024-04-10 | 4.0 | 2024-02-05 | 3.5 |
| 2024-04-09 | 4.0 | 2024-02-02 | 3.6 |
| 2024-04-08 | 4.0 | 2024-02-01 | 3.6 |
| 2024-04-05 | 3.9 | 2024-01-31 | 3.6 |
| 2024-04-04 | 4.1 | 2024-01-30 | 3.7 |
| 2024-04-03 | 4.2 | 2024-01-29 | 3.6 |
| 2024-04-02 | 4.2 | 2024-01-26 | 3.7 |
| 2024-03-28 | 4.1 | 2024-01-25 | 3.6 |
| 2024-03-27 | 4.1 | 2024-01-24 | 3.7 |
| 2024-03-26 | 4.0 | 2024-01-23 | 3.5 |
| 2024-03-25 | 4.0 | 2024-01-22 | 3.4 |
| 2024-03-22 | 4.1 | 2024-01-19 | 3.3 |
| 2024-03-21 | 4.0 | 2024-01-18 | 3.4 |
| 2024-03-20 | 4.1 | 2024-01-17 | 3.3 |
| 2024-03-19 | 4.2 | 2024-01-16 | 3.4 |
| 2024-03-18 | 4.1 | 2024-01-12 | 3.4 |
| 2024-03-15 | 4.0 | 2024-01-11 | 3.4 |
| 2024-03-14 | 4.2 | 2024-01-10 | 3.4 |
| 2024-03-13 | 3.9 | 2024-01-09 | 3.3 |
| 2024-03-12 | 3.9 | 2024-01-08 | 3.4 |
| 2024-03-11 | 3.8 | 2024-01-05 | 3.4 |
| 2024-03-08 | 4.0 | 2024-01-04 | 3.4 |
| 2024-03-07 | 4.0 | 2024-01-03 | 3.4 |
| 2024-03-06 | 3.9 | 2024-01-02 | 3.6 |
| 2024-03-05 | 3.9 | 2023-12-29 | 3.3 |
| 2024-03-04 | 3.9 | 2023-12-28 | 3.4 |
| 2024-03-01 | 3.8 | 2023-12-27 | 69.3 |
| 2024-02-29 | 3.9 | 2023-12-22 | 67.3 |
| 2024-02-28 | 3.8 | 2023-12-21 | 66.1 |
| 2024-02-27 | 3.8 | 2023-12-20 | 68.1 |
| 2024-02-26 | 3.5 | 2023-12-19 | 64.7 |
| 2024-02-23 | 3.5 | 2023-12-18 | 65.5 |
| 2024-02-22 | 3.5 | 2023-12-15 | 64.6 |
| 2024-02-21 | 3.6 | 2023-12-14 | 66.1 |
| 2024-02-20 | 3.6 | 2023-12-13 | 64.3 |
| 2024-02-19 | 3.6 | 2023-12-12 | 63.7 |
| 2024-02-16 | 3.6 | 2023-12-11 | 65.4 |
| 2024-02-15 | 3.6 | 2023-12-08 | 65.9 |
| 2024-02-14 | 3.4 | 2023-12-07 | 62.7 |
Spero Therapeutics Inc (STU:2HA) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Spero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US84833T1034
Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers